Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation.
Taru HallinenErkki SoiniChristian AsseburgMiika LinnaPia ElorantaSari SintonenMikko KosunenPublished in: ClinicoEconomics and outcomes research : CEOR (2021)
In this modelling study, apixaban dominated other anticoagulants in the Finnish real-life setting.